These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14581143)

  • 21. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
    Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
    Takiguchi Y; Wada K; Nakashima M
    Eur J Pharmacol; 1992 May; 215(2-3):289-91. PubMed ID: 1396993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of aldose reductase inhibitors on prostacyclin (PGI2) synthesis by aortic rings from rats with streptozotocin-induced diabetes.
    Wakasugi M; Noguchi T; Inoue M; Tawata M; Shindo H; Onaya T
    Prostaglandins Leukot Essent Fatty Acids; 1991 Dec; 44(4):233-6. PubMed ID: 1840007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
    Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
    Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
    Toyoda F; Tanaka Y; Ota A; Shimmura M; Kinoshita N; Takano H; Matsumoto T; Tsuji J; Kakehashi A
    J Diabetes Res; 2014; 2014():672590. PubMed ID: 25215304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inhibition effect of epalrestat on rat lens osmotic expansion].
    Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts.
    Calderone V; Testai L; Martelli A; La Motta C; Sartini S; Da Settimo F; Breschi MC
    J Pharm Pharmacol; 2010 Jan; 62(1):107-13. PubMed ID: 20723006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
    Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats.
    Jaiswal S; Mishra S; Torgal SS; Shengule S
    Life Sci; 2018 Aug; 207():364-371. PubMed ID: 29936149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
    Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
    Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
    Liu TP; Juang SW; Cheng JT; Tong YC
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):131-5. PubMed ID: 15936525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of an aldose reductase inhibitor, ONO-2235, to streptozotocin-diabetic mice restores reductions of DRG neuronal attachment to extracellular matrix proteins in vitro.
    Sango K; Horie H; Inoue S
    Neurosci Lett; 1999 Mar; 263(2-3):157-60. PubMed ID: 10213159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
    Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):438-42. PubMed ID: 15821963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats.
    Hosotani H; Ohashi Y; Kinoshita S; Matsumoto T; Awata T
    Curr Eye Res; 1996 Oct; 15(10):1005-7. PubMed ID: 8921238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.